Evonik launches recombinant collagen Vecollan® for use in clinical studies
- Clinical-grade Vecollan® available for innovative medical device development.
- Offering validated material starting in 2026.
- Next-generation recombinant collagen shows potential in diverse medical device applications such as orthopedics, medical aesthetics, and sports medicine.
Evonik’s Vecollan® recombinant, non-animal-derived collagen-like protein platform is now available in a grade suitable for use in clinical trials. The new grade marks a significant process scale-up milestone for this new biomaterial, supporting the development of medical devices that improve safety and performance for patients.
The new clinical-grade Vecollan® is an innovation in biosynthetic processing, enabling advancements in various medical fields. Notably, forms of Vecollan® such as sponges and hydrogels have shown particular promise in applications including orthopedics, medical aesthetics, and sports medicine. The new grade not only underscores Evonik's dedication to innovative medical technology solutions but also provides partners with a reliable biomaterial that meets the stringent requirements for clinical use.
"Our new Vecollan® grade is another step forward in our mission to provide high-quality, non-animal-derived collagen alternatives for medical applications and to push the boundaries of medical technology. Now, we are actively seeking collaborations with partners to facilitate entry into clinical trials," said Jeff Smith, head of medical devices at Evonik’s Health Care business line.
Evonik is set to offer partners validated material in 2026, further enhancing the potential applications of Vecollan® in the medical device industry and providing a rapid commercialization pathway. The recombinant collagen-like protein is produced through a sustainable fermentation-based process that ensures high purity and consistency, addressing common concerns associated with animal-derived collagens, such as variability and potential allergic reactions.
Collagen, a vital protein found in bones, muscles, skin, and tendons, serves as a structural scaffold that provides strength and support to various tissues. In medical devices, it facilitates healing and tissue regeneration. With its tunable properties and compatibility with widely used processing technologies, Vecollan® is a safe and sustainable alternative for the medical device industry.
Evonik: Leading beyond chemistry
Evonik goes beyond the boundaries of chemistry with its combination of innovative strength and leading technological expertise. The global chemical company, headquartered in Essen, Germany, is active in more than 100 countries and generated sales of €15.2 billion and earnings (adjusted EBITDA) of €2.1 billion in 2024. The common motivation of the approximately 32,000 employees: to provide customers with a decisive competitive advantage with tailor-made products and solutions as a superforce for industry, thereby improving people's lives. In all markets. Every day.
Asia Pacific is a strong driving force of the global economy and an important source of innovation. Consequently Evonik endeavors to further grow its business in the region. Sales reached €3.28 billion in 2024 and the company employs over 5,000 people at more than 50 sites in Asia Pacific.
Disclaimer
In so far as forecasts or expectations are expressed in this release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.